Question 1

What amounts of liraglutide did the published trials use?

Accepted Answer

Three amounts carry the whole record, and each one belongs to a different question. The lowest is 1·2 mg a day. A 30-week diabetes trial chose it because it was the current most frequently prescribed liraglutide dose in Europe, and set it against weekly semaglutide. The middle amount is 1·8 mg a day. A 48-week phase 2 trial in people with fatty liver inflammation gave subcutaneous injections of liraglutide at 1·8 mg daily against placebo. The top amount is 3·0 mg a day, and it runs through every weight trial covered here. The SCALE Insulin trial randomised 198 people to liraglutide 3·0 mg and 198 to placebo for 56 weeks. A Copenhagen trial gave liraglutide (3·0 mg per day) for a year, and a Texas trial gave the same amount for 40 weeks with MRI scans of belly fat. Read those as three separate experiments rather than three rungs of one ladder. None of the trials covered here compared two liraglutide amounts against each other, so the record tells you what each amount did in its own population and not what moving between them does.

Question 2

What does the approved liraglutide label cover?

Accepted Answer

The weight approval is tied to one figure. A 2019 development history records that significant weight loss, through an effect to reduce energy intake, led to the approval of liraglutide at 3·0 mg for obesity. The diabetes approval came first, and a 2011 review calls liraglutide the first once-daily human GLP-1 analogue developed for type 2 diabetes. A 2023 JAMA review lists liraglutide among six medications currently approved by the US Food and Drug Administration for long-term use in obesity. We report those because they are regulatory facts, in the same way a page would report that a compound is approved for nothing. They are not a view of ours about what anyone should take. The label also prints a step-up schedule for the first weeks. That schedule is not in the research behind this page, so it is not reproduced here, and a reader who wants it will find it on the leaflet in the carton rather than in a summary that could drift from it.

Question 3

How was liraglutide given, and how often?

Accepted Answer

Once a day, under the skin, every time. A 2011 review gives the reason, describing a half-life after injection that makes it suitable for once-daily dosing. A half-life is the time it takes for half of an injected amount to clear the blood. At least one trial put the injection in the participants' own hands, describing subcutaneous self-injections of once-daily liraglutide 3·0 mg as its active comparison arm. One slip in the published record is worth knowing about. A 2025 pooled analysis describes liraglutide at 3·0 mg weekly or 1·8 mg daily, although every 3·0 mg trial behind this page that states its interval gave it once a day. That is almost certainly a wording error in one summary rather than a weekly regimen anyone tested, and it shows how easily a schedule changes as it is copied from paper to paper. A weekly 3·0 mg injection of liraglutide does not appear in any trial covered here, which makes it a different exposure rather than a variant of the studied one.

Question 4

What was the starting amount in the liraglutide trials?

Accepted Answer

The abstracts behind this page report the amount each arm reached rather than the amount it began at, and that is worth being plain about before reading anything else into them. The trial in young people with type 2 diabetes is the clearest sign that a climb happened at all, because it describes liraglutide given at up to 1·8 mg per day rather than at a single fixed figure. The dose-finding trial that used liraglutide as a comparator describes a 26-week treatment period, including a dose-escalation period of up to 6 weeks, which is the run of weeks spent stepping upward before the assigned amount is held. That escalation window covers every active arm in that trial rather than liraglutide alone, so it says nothing precise about the liraglutide steps. The honest summary is that the trials climbed to their amounts and the abstracts do not print the rungs. The label does, and it is the document that holds them.

Question 5

How many doses does an 18 mg liraglutide pen hold?

Accepted Answer

The pens on the recall register state their strength, describing Saxenda (liraglutide) Injection, 18 mg/3 mL (6 mg/mL), in a single 3 mL prefilled pen. The Victoza pen listed on the same day carries the same 18 mg/3 mL (6 mg/mL) strength. From there it is division. Eighteen milligrams holds six amounts of 3·0 mg, ten of 1·8 mg, or fifteen of 1·2 mg. At 6 mg in every millilitre, 3·0 mg is half a millilitre of liquid, 1·8 mg is 0·3 mL and 1·2 mg is 0·2 mL. Those figures are arithmetic on a printed strength rather than anything a study measured, and the pen's own leaflet governs how it is actually used. They also hold only at 6 mg/mL. A vial at any other strength changes every number in this section, and the arithmetic for a powder that has to be mixed is worked through on the reconstitution calculator, which takes your numbers and suggests none of its own.

Question 6

What amounts of liraglutide were used in children?

Accepted Answer

Two trials went below adult age. In the first, patients who were 10 to less than 17 years of age were randomly assigned to subcutaneous liraglutide at up to 1·8 mg per day or to placebo. Those children all had type 2 diabetes, and all the patients received metformin during the trial, so the amount was given alongside another medicine rather than on its own. The second trial went younger, to children aged 6 to under 12 with obesity, and ran a 56-week treatment period followed by a 26-week follow-up period. Its abstract reports the result but not the amount the children received, so this page does not supply one. Filling that blank with the adult weight figure would be a guess presented as a fact, and an amount for a six-year-old is the last place a guess belongs.

Question 7

How much liraglutide is in Xultophy?

Accepted Answer

Xultophy puts liraglutide in the same pen as a long-acting insulin, and its listing gives both strengths as 100 units/mL and 3·6 mg/mL. Because the two sit in one liquid at a fixed ratio, the amount of liraglutide a person receives from that pen is set by the insulin units dialled rather than chosen separately. Every 10 units of insulin carry 0·36 mg of liraglutide, by simple division on the label strengths. How fast to climb on that combined pen was itself the subject of a completed trial, which compared insulin degludec and liraglutide in people with type 2 diabetes using two different titration algorithms. Titration means stepping an amount up or down by a rule. The point for anyone comparing figures is that a Xultophy amount and a Saxenda amount are not the same kind of number, since one rides on insulin units and the other is measured in milligrams of liraglutide alone.

Question 8

How much weight can you lose on Saxenda in 3 months?

Accepted Answer

No trial among these sources reports a weight figure at three months on 3·0 mg, and the one that comes closest shows why an early number is easy to misread. The Copenhagen trial put everyone on an 8-week low-calorie diet before any injection, and after that diet, 195 participants had a mean decrease in body weight of 13·1 kg. Only then did the injections begin, and at one year the liraglutide group had lost 6·8 kg more than the placebo group. Read that sequence carefully. The large early drop in that trial came from the diet, before liraglutide was given, and the injection's job was to hold and extend it over the following year. So a three-month figure quoted for Saxenda is either arithmetic done on a later average or a number from a programme that bundled a diet with the pen. Neither is a measurement of what three months of liraglutide does, and the trial endpoints themselves are set out on the main the Liraglutide overview page.

Question 9

Is there a cycle or a break in the liraglutide research?

Accepted Answer

Among these sources, no trial put an on-and-off pattern to the test. Every arm ran continuously to its endpoint and then stopped, which makes the one stop that was followed up the closest thing to a break in the record. That follow-up came from Copenhagen, where weight regain in the year after stopping was 6·0 kg larger after termination of liraglutide compared with after termination of supervised exercise. The authors summed it up as body weight maintained one year after supervised exercise ended, in contrast to weight regain after termination of treatment with obesity pharmacotherapy alone. A 2025 real-world review lists studies of the effects of stopping GLP-1RA treatment among the areas still needing research. So stopping has been measured once, as a full stop after a year, and a cycle has not been measured at all. Those are different questions, and the first answer does not tell you anything about the second.

Question 10

Does the approved amount apply to compounded or research-grade liraglutide?

Accepted Answer

No, and the reason is a matter of what the figure is attached to rather than a matter of chemistry. Every amount on this page was given from a pen made to a filed strength, and the recall register shows how much that strength depends on handling. Sample pens stored below 32°F were pulled because the cold could cause a lack of efficacy and damage to the cartridge. A pen kept too cold can stop delivering what its label says, and that pen at least has a label to fall short of. A compounded or research-grade vial has no approved strength, no batch on the register and no trial behind it. The approval itself names a molecule at an amount for a use, recorded as liraglutide at 3·0 mg for obesity, and it does not travel to a container nobody licensed. So 3·0 mg on a vial is a number, while 3·0 mg in a Saxenda pen is a number with a specification and a regulator behind it. They are different things that happen to share a figure.

Question 11

Why do the published liraglutide amounts vary?

Accepted Answer

Because each trial chose its amount to answer its own question, and the choice is usually stated. The diabetes comparison picked 1·2 mg to mirror practice, comparing the anticipated most frequent semaglutide dose with the most often prescribed liraglutide dose, reflecting clinical practice. The liver trial picked 1·8 mg, the higher of the two diabetes amounts in these trials, and the weight trials took the amount that carried the obesity approval. Outside trials the picture shifts again, since a 2025 review of real-world use reports the use of much lower doses than those evaluated in clinical trials across this class. That last finding describes what people did rather than what anyone tested. A lower amount taken in ordinary life is a different exposure from every published arm, and whether it does anything at that size is a question none of these trials was designed to ask.

Trial	Daily amount	Compared with	Length
Diabetes trial	1·2 mg	Weekly semaglutide	30 weeks
Phase 2 trial, fatty liver inflammation	1·8 mg	Placebo	48 weeks
SCALE Insulin, 198 per arm	3·0 mg	Placebo	56 weeks
Copenhagen trial	3·0 mg	Not stated here	A year
Texas trial, MRI of belly fat	3·0 mg	Not stated here	40 weeks

Liraglutide protocols in the published literature